45 related articles for article (PubMed ID: 20177382)
1. The Challenge of Classifying Metastatic Cell Properties by Molecular Profiling Exemplified with Cutaneous Melanoma Cells and Their Cerebral Metastasis from Patient Derived Mouse Xenografts.
Neuditschko B; Janker L; Niederstaetter L; Brunmair J; Krivanek K; Izraely S; Sagi-Assif O; Meshel T; Keppler BK; Del Favero G; Witz IP; Gerner C
Mol Cell Proteomics; 2020 Mar; 19(3):478-489. PubMed ID: 31892524
[TBL] [Abstract][Full Text] [Related]
2. Tumor infiltrating lymphocytes: The regulator of melanoma evolution.
Antohe M; Nedelcu RI; Nichita L; Popp CG; Cioplea M; Brinzea A; Hodorogea A; Calinescu A; Balaban M; Ion DA; Diaconu C; Bleotu C; Pirici D; Zurac SA; Turcu G
Oncol Lett; 2019 May; 17(5):4155-4161. PubMed ID: 30944610
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathology of cutaneous melanoma.
van Kempen LC; Redpath M; Robert C; Spatz A
Melanoma Manag; 2014 Nov; 1(2):151-164. PubMed ID: 30190820
[TBL] [Abstract][Full Text] [Related]
4. Effect of biology on the outcome of female melanoma patients.
Erturk K; Tas F
Mol Clin Oncol; 2017 Dec; 7(6):1093-1100. PubMed ID: 29285381
[TBL] [Abstract][Full Text] [Related]
5. Autophagic UVRAG Promotes UV-Induced Photolesion Repair by Activation of the CRL4(DDB2) E3 Ligase.
Yang Y; He S; Wang Q; Li F; Kwak MJ; Chen S; O'Connell D; Zhang T; Pirooz SD; Jeon YH; Chimge NO; Frenkel B; Choi Y; Aldrovandi GM; Oh BH; Yuan Z; Liang C
Mol Cell; 2016 May; 62(4):507-19. PubMed ID: 27203177
[TBL] [Abstract][Full Text] [Related]
6. Host kinin B1 receptor plays a protective role against melanoma progression.
Maria AG; Dillenburg-Pilla P; Reis RI; Floriano EM; Tefé-Silva C; Ramos SG; Pesquero JB; Nahmias C; Costa-Neto CM
Sci Rep; 2016 Feb; 6():22078. PubMed ID: 26898917
[TBL] [Abstract][Full Text] [Related]
7. Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.
de Moll EH; Fu Y; Qian Y; Perkins SH; Wieder S; Gnjatic S; Remark R; Bernardo SG; Moskalenko M; Yao J; Ferringer T; Chang R; Chipuk J; Horst BA; Birge MB; Phelps RG; Saenger YM
Cancer Immunol Immunother; 2015 Sep; 64(9):1193-203. PubMed ID: 26076664
[TBL] [Abstract][Full Text] [Related]
8. The clinicopathological and gene expression patterns associated with ulceration of primary melanoma.
Jewell R; Elliott F; Laye J; Nsengimana J; Davies J; Walker C; Conway C; Mitra A; Harland M; Cook MG; Boon A; Storr S; Safuan S; Martin SG; Jirström K; Olsson H; Ingvar C; Lauss M; Bishop T; Jönsson G; Newton-Bishop J
Pigment Cell Melanoma Res; 2015 Jan; 28(1):94-104. PubMed ID: 25220403
[TBL] [Abstract][Full Text] [Related]
9. Melanoma risk loci as determinants of melanoma recurrence and survival.
Rendleman J; Shang S; Dominianni C; Shields JF; Scanlon P; Adaniel C; Desrichard A; Ma M; Shapiro R; Berman R; Pavlick A; Polsky D; Shao Y; Osman I; Kirchhoff T
J Transl Med; 2013 Nov; 11():279. PubMed ID: 24188633
[TBL] [Abstract][Full Text] [Related]
10. Do not underestimate nucleotide excision repair: it predicts not only melanoma risk but also survival outcome.
Emmert S; Kraemer KH
J Invest Dermatol; 2013 Jul; 133(7):1713-7. PubMed ID: 23760049
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of nucleotide excision repair genes predict melanoma survival.
Li C; Yin M; Wang LE; Amos CI; Zhu D; Lee JE; Gershenwald JE; Grimm EA; Wei Q
J Invest Dermatol; 2013 Jul; 133(7):1813-21. PubMed ID: 23407396
[TBL] [Abstract][Full Text] [Related]
12. Sox4-mediated Dicer expression is critical for suppression of melanoma cell invasion.
Jafarnejad SM; Ardekani GS; Ghaffari M; Martinka M; Li G
Oncogene; 2013 Apr; 32(17):2131-9. PubMed ID: 22689055
[TBL] [Abstract][Full Text] [Related]
13. Towards a quantitative understanding of the MITF-PIAS3-STAT3 connection.
Thingnes J; Lavelle TJ; Gjuvsland AB; Omholt SW; Hovig E
BMC Syst Biol; 2012 Feb; 6():11. PubMed ID: 22316093
[TBL] [Abstract][Full Text] [Related]
14. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.
Meyer C; Sevko A; Ramacher M; Bazhin AV; Falk CS; Osen W; Borrello I; Kato M; Schadendorf D; Baniyash M; Umansky V
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17111-6. PubMed ID: 21969559
[TBL] [Abstract][Full Text] [Related]
15. The biology behind prognostic factors of cutaneous melanoma.
Spatz A; Batist G; Eggermont AM
Curr Opin Oncol; 2010 May; 22(3):163-8. PubMed ID: 20177382
[TBL] [Abstract][Full Text] [Related]
16. The biology of melanoma prognostic factors.
Spatz A; Stock N; Batist G; van Kempen LC
Discov Med; 2010 Jul; 10(50):87-93. PubMed ID: 20670603
[TBL] [Abstract][Full Text] [Related]
17. Microstaging in cutaneous melanoma.
Ruiter DJ; Spatz A; van den Oord JJ; Cook MG;
J Pathol; 2001 Dec; 195(5):525-9. PubMed ID: 11745686
[TBL] [Abstract][Full Text] [Related]
18. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
[TBL] [Abstract][Full Text] [Related]
19. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
